Institution · Actelion (Switzerland)
Most cited papers from Actelion (Switzerland)
What are the most cited papers from Actelion (Switzerland)?
The most cited paper from Actelion (Switzerland) is "Bosentan Therapy for Pulmonary Arterial Hypertension" (Lewis J. Rubin, David B. Badesch, Robyn J. Barst et al., 2002), with 2,736 citations. Next come "DataWarrior: An Open-Source Program For Chemistry Aware Data Visualization And Analysis" (1,871) and "Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study" (1,537).
Showing 50 of 59 papers. Every paper with more than 170 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | Bosentan Therapy for Pulmonary Arterial Hypertension Lewis J. Rubin, David B. Badesch, Robyn J. Barst et al. · New England Journal of Medicine | 21 Mar 2002 | 2,736 |
| 2 | DataWarrior: An Open-Source Program For Chemistry Aware Data Visualization And Analysis Thomas Sander, Joël Freyss, Modest von Korff et al. · Journal of Chemical Information and Modeling | 5 Jan 2015 | 1,871 |
| 3 | Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study Richard N. Channick, Gérald Simonneau, Olivier Sitbon et al. · The Lancet | Oct 2001 | 1,537 |
| 4 | Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension Tomás Pulido, Igor Adzerikho, Richard N. Channick et al. · New England Journal of Medicine | 28 Aug 2013 | 1,457 |
| 5 | Selexipag for the Treatment of Pulmonary Arterial Hypertension Olivier Sitbon, Richard N. Channick, Kelly Chin et al. · New England Journal of Medicine | 23 Dec 2015 | 1,071 |
| 6 | Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial Nazzareno Galiè, LJ Rubin, Marius M. Hoeper et al. · The Lancet | Jun 2008 | 924 |
| 7 | Bosentan Therapy in Patients With Eisenmenger Syndrome Nazzareno Galiè, Maurice Beghetti, Michael Athanassios Gatzoulis et al. · Circulation | 26 Jun 2006 | 846 |
| 8 | Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study Gerry Coghlan, Christopher P. Denton, Ekkehard Grünig et al. · Annals of the Rheumatic Diseases | 18 May 2013 | 838 |
| 9 | Digital ulcers in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonist J H Korn et al. · Arthritis & Rheumatism | Dec 2004 | 729 |
| 10 | BUILD-3: A Randomized, Controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis Talmadge E. King, Kevin M. Brown, Ganesh Raghu et al. · American Journal of Respiratory and Critical Care Medicine | 7 Apr 2011 | 722 |
| 11 | Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease Kim S. Midwood, Sandra M. Sacre, Anna Maria Piccinini et al. · Nature Medicine | 28 Jun 2009 | 710 |
| 12 | Clazosentan to Overcome Neurological Ischemia and Infarction Occurring After Subarachnoid Hemorrhage (CONSCIOUS-1) Robert Loch Macdonald, Neal F. Kassell, Stephan A. Mayer et al. · Stroke | 7 Aug 2008 | 651 |
| 13 | Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2) R. Loch Macdonald, Randall T. Higashida, E. Keller et al. · The Lancet Neurology | 3 Jun 2011 | 646 |
| 14 | Survival with first-line bosentan in patients with primary pulmonary hypertension Vallerie V. McLaughlin, O. Sitbon, D. B. Badesch et al. · European Respiratory Journal | 31 Jan 2005 | 605 |
| 15 | Promotion of sleep by targeting the orexin system in rats, dogs and humans Catherine Brisbare‐Roch, Jasper Dingemanse, Ralf Koberstein et al. · Nature Medicine | 28 Jan 2007 | 572 |
| 16 | Bosentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension Xavier Jaïs, Andrea Maria D’Armini, Pavel Jansa et al. · Journal of the American College of Cardiology | Dec 2008 | 553 |
| 17 | Five-Year Outcomes of Patients Enrolled in the REVEAL Registry Harrison W. Farber, Dave P. Miller, Abby D. Poms et al. · CHEST Journal | 11 Jun 2015 | 528 |
| 18 | BUILD-1: A Randomized Placebo-controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis Talmadge E. King, Jürgen Behr, Kevin M. Brown et al. · American Journal of Respiratory and Critical Care Medicine | 28 Sep 2007 | 503 |
| 19 | Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial Marco Matucci‐Cerinic, CP Denton, Daniel E Furst et al. · Annals of the Rheumatic Diseases | 31 Aug 2010 | 503 |
| 20 | Prediction of Pulmonary Complications and Long‐Term Survival in Systemic Sclerosis Svetlana I. Nihtyanova, Benjamin Emmanuel Schreiber, Voon Hong Ong et al. · Arthritis & Rheumatology | 3 Mar 2014 | 465 |
| 21 | Prevalence of HIV-Related Pulmonary Arterial Hypertension in the Current Antiretroviral Therapy Era Olivier Sitbon, Caroline Lascoux‐Combe, Jean‐François Delfraissy et al. · American Journal of Respiratory and Critical Care Medicine | 20 Dec 2007 | 458 |
| 22 | Response Assessment in Neuro-Oncology Clinical Trials Patrick Yung Wen, Susan Marina Chang, Martin J. van den Bent et al. · Journal of Clinical Oncology | 22 Jun 2017 | 446 |
| 23 | Effects of the oral endothelin-receptorantagonist bosentan on echocardiographicand doppler measures in patients with pulmonary arterial hypertension Nazzareno Galiè, Alan L. Hinderliter, Adam Torbicki et al. · Journal of the American College of Cardiology | Apr 2003 | 378 |
| 24 | Effects of Tezosentan on Symptoms and Clinical Outcomes in Patients With Acute Heart Failure John J.V. McMurray, John R. Teerlink, Gad Cotter et al. · JAMA | 6 Nov 2007 | 359 |
| 25 | Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension Robyn J. Barst · Clinical Pharmacology & Therapeutics | Apr 2003 | 351 |
| 26 | Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist Marc Iglarz, Christoph A. Binkert, Keith Morrison et al. · Journal of Pharmacology and Experimental Therapeutics | 9 Sep 2008 | 328 |
| 27 | Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension Gérald Simonneau, Adam Torbicki, Marius M. Hoeper et al. · European Respiratory Journal | 23 Feb 2012 | 316 |
| 28 | Bosentan Is a Substrate of Human OATP1B1 and OATP1B3: Inhibition of Hepatic Uptake as the Common Mechanism of Its Interactions with Cyclosporin A, Rifampicin, and Sildenafil Alexander Treiber, R Schneiter, Stéphanie Häusler et al. · Drug Metabolism and Disposition | 12 May 2007 | 299 |
| 29 | Results of European post-marketing surveillance of bosentan in pulmonary hypertension Marc Humbert, Eleanor S Segal, David Gerard Kiely et al. · European Respiratory Journal | 15 May 2007 | 296 |
| 30 | Industrial Applications of the Diels–Alder Reaction Jacques‐Alexis Funel, Stefan Abele · Angewandte Chemie International Edition | 27 Feb 2013 | 296 |
| 31 | Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial Ganesh Raghu, Rachel Million-Rousseau, Adele Morganti et al. · European Respiratory Journal | 16 May 2013 | 280 |
| 32 | OSIRIS, an Entirely in-House Developed Drug Discovery Informatics System Thomas Sander, Joël Freyss, Modest von Korff et al. · Journal of Chemical Information and Modeling | 14 Jan 2009 | 280 |
| 33 | Optical polymer thin films with isotropic and anisotropic nano-corrugated surface topologies Mohammed Ibn‐Elhaj, Martin Schadt · Nature | Apr 2001 | 277 |
| 34 | Clinical Pharmacology of Bosentan, a Dual Endothelin Receptor Antagonist Jasper Dingemanse, Paul L. M. van Giersbergen · Clinical Pharmacokinetics | 2004 | 273 |
| 35 | Effects of Long-Term Bosentan in Children With Pulmonary Arterial Hypertension Erika B. Rosenzweig, D. Dunbar Ivy, Allison C. Widlitz et al. · Journal of the American College of Cardiology | 20 Jul 2005 | 264 |
| 36 | Bosentan for the Treatment of Human Immunodeficiency Virus–associated Pulmonary Arterial Hypertension Olivier Sitbon, Virginie Gressin, Rudolf Speich et al. · American Journal of Respiratory and Critical Care Medicine | 18 Aug 2004 | 260 |
| 37 | Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: Results of the BREATHE-5 open-label extension study Michael Athanassios Gatzoulis, Maurice Beghetti, Nazzareno Galiè et al. · International Journal of Cardiology | 21 Jul 2007 | 248 |
| 38 | Second messenger signalling governs Escherichia coli biofilm induction upon ribosomal stress Alex M. Boehm, Samuel Steiner, Franziska Zaehringer et al. · Molecular Microbiology | 18 May 2009 | 243 |
| 39 | Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identification of the most accurate estimates from a systematic literature review Laurence Leber, Amélie Beaudet, Audrey Muller · Pulmonary Circulation | 13 Nov 2020 | 238 |
| 40 | YfiBNR Mediates Cyclic di-GMP Dependent Small Colony Variant Formation and Persistence in Pseudomonas aeruginosa Jacob G. Malone, Tina Jaeger, Christian Spangler et al. · PLoS Pathogens | 11 Mar 2010 | 237 |
| 41 | Resolution Pharmacology: Opportunities for Therapeutic Innovation in Inflammation Mauro Perretti, Xavier Leroy, Elliot J. Bland et al. · Trends in Pharmacological Sciences | Nov 2015 | 235 |
| 42 | Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension Vallerie V. McLaughlin, Richard N. Channick, Hossein-Ardeschir Ghofrani et al. · European Respiratory Journal | 25 Jun 2015 | 230 |
| 43 | Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study Ludwig Kappos, Robert J. Fox, Michel Burcklen et al. · JAMA Neurology | 29 Mar 2021 | 226 |
| 44 | Evaluation of tert‐Butyl Isosteres: Case Studies of Physicochemical and Pharmacokinetic Properties, Efficacies, and Activities Matthias V. Westphal, Bernd T. Wolfstädter, Jean‐Marc Plancher et al. · ChemMedChem | 28 Jan 2015 | 214 |
| 45 | Burden of illness in idiopathic pulmonary fibrosis Harold R. Collard, Alex Ward, Stephan Lanes et al. · Journal of Medical Economics | 28 Mar 2012 | 212 |
| 46 | Recommendations for Screening and Detection of Connective Tissue Disease–Associated Pulmonary Arterial Hypertension Dinesh Khanna, Heather S. Gladue, Richard N. Channick et al. · Arthritis & Rheumatism | 11 Sep 2013 | 212 |
| 47 | Macitentan in pulmonary hypertension due to left ventricular dysfunction Jean‐Luc Vachiéry, Marion Delcroix, Hikmet Al‐Hiti et al. · European Respiratory Journal | Feb 2018 | 209 |
| 48 | Miglustat in adult and juvenile patients with Niemann–Pick disease type C: Long-term data from a clinical trial James Edmond Wraith, Darleen Vecchio, Elizabeth Jacklin et al. · Molecular Genetics and Metabolism | 17 Dec 2009 | 209 |
| 49 | Disease and patient characteristics in NP-C patients: findings from an international disease registry Marc C. Patterson, Eugen Mengel, Frits A. Wijburg et al. · Orphanet Journal of Rare Diseases | 2013 | 200 |
| 50 | Aliskiren Reduces Blood Pressure and Suppresses Plasma Renin Activity in Combination With a Thiazide Diuretic, an Angiotensin-Converting Enzyme Inhibitor, or an Angiotensin Receptor Blocker Eoin T O'Brien, John Barton, Juerg Nussberger et al. · Hypertension | 12 Dec 2006 | 200 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.